Complete Guide to T-DXd (Enhertu) PBPK-PD ILD Risk Pharmacokinetics
Overview
T-DXd (Enhertu) PBPK-PD ILD Risk is a Antibody-Drug Conjugate (ADC) used in the Oncology / Breast Cancer therapeutic area. It is indicated for HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization. Interactive PBPK-PD simulator for T-DXd (Enhertu, trastuzumab deruxtecan) predicting DXd lung exposure and ILD risk probability across doses (3.2–6.4 mg/kg) and patient age (50–80 years). Based on the Wang et al. 2025 mechanistic PBPK model. Essential tool for understanding interstitial lung disease risk stratification in HER2-targeted ADC therapy.
Mechanism of Action
T-DXd (Enhertu) PBPK-PD ILD Risk exerts its pharmacological effect by targeting HER2 (ERBB2). As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PBPK-PD models for T-DXd (Enhertu) PBPK-PD ILD Risk:
| Parameter | Value |
|---|---|
| DXd Lung IC10 | 17 |
| DXd Lung IC20 | 38.25 |
| DXd Lung IC50 | 153 |
| T-DXd Clearance (CL) | 0.42 |
| DXd Yield per ADC (FGEN) | 4.1 |
| T-DXd Central Volume (V1) | 2.68 |
| ADC Lung Uptake Rate (KIN L) | 0.0058 |
| T-DXd Peripheral Volume (V2) | 2.06 |
| DXd Lung Efflux Rate (KOUT L) | 0.05 |
| Endosomal Processing Rate (KPROC) | 0.0085 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
T-DXd (Enhertu) PBPK-PD ILD Risk is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology / Breast Cancer therapeutic area, for the treatment of HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization, understanding the pharmacokinetics of T-DXd (Enhertu) PBPK-PD ILD Risk is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect T-DXd (Enhertu) PBPK-PD ILD Risk pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive T-DXd (Enhertu) PBPK-PD ILD Risk PK Simulator
Explore T-DXd (Enhertu) PBPK-PD ILD Risk pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of T-DXd (Enhertu) PBPK-PD ILD Risk?
The elimination half-life of T-DXd (Enhertu) PBPK-PD ILD Risk depends on patient-specific factors. Use our interactive T-DXd (Enhertu) PBPK-PD ILD Risk PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is T-DXd (Enhertu) PBPK-PD ILD Risk administered?
T-DXd (Enhertu) PBPK-PD ILD Risk is administered via the IV Infusion route. It is indicated for HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization. As a Antibody-Drug Conjugate (ADC), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of T-DXd (Enhertu) PBPK-PD ILD Risk?
Key pharmacokinetic parameters for T-DXd (Enhertu) PBPK-PD ILD Risk include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate T-DXd (Enhertu) PBPK-PD ILD Risk dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive T-DXd (Enhertu) PBPK-PD ILD Risk PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.